Pharmacy Drugs
Recent Posts
- Democrats Push Medical Device Liability Bill
- FDA Investigates Heparin Link in Two Delaware Deaths
- Conflict Of Interest Reported In 29 Percent Of Cancer Studies
- Interim Results Of Abbott’s PROGRESS Study Show Rapid Viral Decline In Dual-Therapy Regimen Of Kaletra(R) (lopinavir/ritonavir) And Raltegravir
- Survival For Prostate Cancer Patients Younger Than 50 Improved By Surgery
Random Posts
- Altus Pharmaceuticals Reports Dosing First Patient In A Phase 2 Trial Of ALTU-238 For Pediatric Growth Hormone Deficiency
- Excellence In Oncology Awards 2009 Now Open For Entry
- Hospital Trust Recruiting For Trials Of New Flu Vaccine, UK
- 5-Year Study Published In Diabetologia Demonstrated Long-Term Safety Of Lantus(R) Compared To NPH
- Cytokinetics To Present Phase IIa Clinical Trials Data On CK-1827452 At The 2009 Heart Failure Congress Of The European Society Of Cardiology
- Immediate Tendonitis Relief Following Rotator Cuff Treatment
- Drug Option For Patients Beginning HIV Treatment Studied
- Gender Difference In Heart Failure
- Report Finds Racial Disparities In Prescription Drug Access, Use, Regimen Adherence
- Nurse Prescribing Welcomed By PSA, Australia
Hydroxycut Supplements Recalled After Liver Damage
Posted by: admin in Pharmacy, Pharmacy Drugs on May 03rd, 2009
WASHINGTON, May 1 — The maker of Hydroxycut supplements, a line of diet aids that sold more than 9 million units last year, has recalled 14 products after reports of severe liver damage, including the death of a 19-year-old man and at least one transplant, the FDA said today.
The agency said the supplement makers — Iovate Health Sciences USA of Blasdell, N.Y., and Iovate Health Sciences of Oakville, Ontario, in Canada — are voluntarily recalling products suspected of hepatotoxicity.
Linda Katz, M.D., M.P.H., interim chief medical officer, at the FDA’s Center for Food Safety and Applied Nutrition (CFSAN), told news media that the agency had received 23 reports of serious health problems, ranging from asymptomatic elevated liver enzymes to liver failure and death.
The death occurred in 2007, but the FDA only learned of it in March 2009. Dr. Katz said the delay was not unusual because supplement manufacturers are subject to voluntary rather than mandatory reporting requirements.
Unlike drug manufacturers, who are strictly regulated, the makers of diet supplements are not required to provide precise ingredient formulae to the FDA — a longstanding issue for regulators seeking to identify the toxicity of specific ingredients.
Supplement makers only provide the FDA with “propriety blend” information, said Vasilios Frankos, Ph.D., director of the FDA’s Division of Dietary Supplement Programs.
So at this point, the FDA does not know if the toxicity was caused by a single ingredient or a mix of ingredients.
Dr. Katz said, however, that the toxic reaction does not appear to be a dose response, nor does it appear related to “long- versus short-term use.”
The recalled products, which are marketed under both Iovate and MuscleTech brands are:
- Hydroxycut Regular Rapid Release Caplets
- ?Hydroxycut Caffeine-Free Rapid Release Caplets ?
- Hydroxycut Hardcore Liquid Caplets ?
- Hydroxycut Max Liquid Caplets
- ?Hydroxycut Regular Drink Packets ?
- Hydroxycut Caffeine-Free Drink Packets ?
- Hydroxycut Hardcore Drink Packets (Ignition Stix)
- ?Hydroxycut Max Drink Packets
- ?Hydroxycut Liquid Shots
- ?Hydroxycut Hardcore RTDs (Ready-to-Drink)
- ?Hydroxycut Max Aqua Shed
- ?Hydroxycut 24 ?
- Hydroxycut Carb Control
- ?Hydroxycut Natural
Two other products marketed under the Iovate or MuscleTech brands, Hydroxycut Cleanse and Hoodia, are not affected by the recall.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.
| Copyright 2009 |online pharmacy ambien no prescription buy xanax online no prescription online tramadol buying xanax online buy soma





